Hereditary Cancer Screening and Risk Reduction Software

Onqueta is a digital solution for identifying people at high risk of cancer for further genetic testing based on ICMR, NCCN, ASCO, ESMO recommendations
What is Onqueta?
Who needs Onqueta?
The burden of cancer continues to grow worldwide, following with enormous physical, emotional and financial consequences for individuals, families, communities and healthcare systems.
Solution does exist!
Cancer, when diagnosed early, is more likely to be treated effectively, increasing the likelihood of survival and reducing the pain associated with anticancer therapy and decreases the cost of treatment.
We designed ONQUETA – a digital identification tool for individuals at risk for hereditary cancer syndromes.
Oncology Clinics
Onqueta helps to increase the flow of clients (patients)
Onqueta increases the quality of diagnosis and treatment services
Medical laboratories performing molecular genetic testing
Onqueta contributes to increase order intake
Onqueta reduces costs for hereditary oncology syndromes (HOS) carriers
Pharmaceutical companies
Onqueta can provide information about frequencies of HOS carriers
Onqueta may help to increase the targeted drugs sale (PARP inhibitors)
Incorporating ONQUETA survey technology as part of the standard of care in patient screenings and/or targeted cancer screenings helps to establish an early diagnosis and/or prevent a person from developing the disease.
How Onqueta works
  • Answer a few questions in Telegram-bot
  • Algorithms propose one of two solutions: to make a genetic diagnosis or not
  • The suggestion is advisory
  • Physician and/or patient may agree with the proposal
* Onqueta can direct the patient to the appropriate clinic/laboratory via geoIP
Syndromes that can be identified by Onqueta
  • BRCA1-2 associated syndrome (breast cancer, ovarian cancer, prostate cancer)
  • Lynch syndrome;
  • Hereditary diffuse gastric cancer;
  • Hereditary pancreatic cancer;
  • Familial adenomatous polyposis;
  • Hereditary mixed polyposis syndrome;
  • Familial atypical moles and melanoma syndrome;
  • Lee-Fraumeni syndrome;
  • Cawden’s syndrome;
  • Peitz-Jeghers syndrome
The above syndromes are diagnosed by these genes:
Oncology: screening and early diagnosis

The benefits of early cancer detection are clear — the quality of life of cancer patients can be greatly improved. Also:

  • Potential reduction in morbidity in the target healthy population with effective detection and appropriate treatment of precancerous lesions as part of a screening program
  • Reduction in the number of late stages at the time of diagnosis in the target population (usually the earlier stage plays a role rather than the fact of early diagnosis)
  • Reduced mortality with effective screening followed by treatment.
Who are our users?

Healthy people who are concerned about their health, including the risk of cancer.

  • Allows to know the individual risks of hereditary cancer
  • Recommends preventive measures in this regard

Oncology patients

  • Let them know about individual risks of hereditary cancer
  • LOnqueta advises where and how to get genetic testing for diagnosis and treatment

Relatives of oncology patients

  • Screening for hereditary cancer risk
  • We recommend taking preventive checkup accompanied by doctors
Physician’s Team
Development team
In 2009-2011 in Russia there was started a study - a project to study hereditary cancer syndromes in the Russian Federation. A database was created and accumulated experience and skills in detecting (identifying) cancer syndromes. Onqueta relies on this knowledge base, on this project.
Marat Gordiev
  • Head of genetic laboratory, Sergey Berezin Medical Institute (MIBS). The laboratory is the reference expert facility for cancer diagnostics covering in total approximately 1/3 of Russia
  • Head of Study on «Hereditary oncology Syndromes in the Russian Federation»
  • Author of the recommendations of Russian Society of Clinical Oncology (RUSSCO)
Novel Software Systems (NOVEL) is an innovative biotechnology company combining molecular biology expertise with data analysis technologies. Our team comprises more than 50 highly qualified Java and Python developers, Data Science and Machine Learning specialists, bioinformatics and biologists, including 15 employees with an academic degree. Most of the results of our research have been published in international scientific journals. We conduct academic courses and invite students for internships. Our mission is to support the development of our clients — biotech companies and scientific organizations, applying our knowledge, experience and qualifications in the field of bioinformatics and information technology.
Dmitry Shtokalo
  • CEO of NOVEL
  • One of the leading experts in the fields of mathematical biology and bioinformatics. Co-author of many scientific publications and projects, including Genomenal NGS Wizard, Genokarta, SLI Environment, ExPlain, etc.
Contact us